1,3,5-三乙酰基-2-脱氧-alpha-D-赤式戊呋喃糖 | 96291-74-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,3,5-三乙酰基-2-脱氧-alpha-D-赤式戊呋喃糖
• 英文名称: (2R,4S,5R)-5-(acetoxymethyl)tetrahydrofuran-2,4-diyl diacetate
• 英文别名: 1,3,5-tri-O-Acetyl-2-Deoxy-alpha-D-Erythro-Pentofuranose；[(2R,3S,5R)-3,5-diacetyloxyoxolan-2-yl]methyl acetate
• CAS: 96291-74-6
• 化学式: C₁₁H₁₆O₇
• mdl: MFCD08458217
• 分子量: 260.244
• InChiKey: QAGMBTAACMQRSS-AXFHLTTASA-N

物化性质

• 沸点：
  329.3±42.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.727
• 拓扑面积：
  88.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1,3,5-三乙酰基-2-脱氧-alpha-D-赤式戊呋喃糖 在 甲醇 、 sodium methylate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 15.5h， 生成 3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-methylpyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
  [FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS

  摘要：

  除其他事项外，本公开提供寡核苷酸及其组合物。在某些实施例中，提供的寡核苷酸及其组合物对腺苷修饰有用。在某些实施例中，本公开提供了治疗各种需要腺苷修饰的疾病、疾病或病症的方法。

  公开号：

  WO2022099159A1
• 作为产物：
  描述：

  2-deoxy-D-ribose 在 4-二甲氨基吡啶 作用下， 以 2-甲基四氢呋喃 为溶剂， 以20%的产率得到
  参考文献：
  名称：

  Green Methods of Carbohydrate Acetylation

  摘要：

  Methods of carbohydrate acetylation are disclosed. A method may include adding a carbohydrate to a reaction vessel, adding poly-4-vinylpyriding (P4VP) to the reaction vessel, adding a bio-derived solvent to the reaction vessel, adding acetic anhydride (Ac20) to the reaction vessel, and adding a catalyst to the reaction vessel. The bio-derived solvent may be 2-methyltetrahydrofuran (2-MeTHF). A catalyst may also be added to the reaction vessel.

  公开号：

  US20230132332A1

文献信息

• PREPARATION OF DECITABINE
  申请人：Kolla Naveen Kumar

  公开号：US20120046457A1

  公开（公告）日：2012-02-23

  The present application relates to processes for the preparation and purification of decitabine structurally represented by formula (I): and to processes for the preparation of a crystalline form of decitabine.

  本申请涉及制备和纯化结构式(I)所代表的脱氧阿糖胞苷的过程，以及制备脱氧阿糖胞苷的晶体形式的过程。
• Process for the Preparation of Cladribine
  申请人：Henschke Julian Paul

  公开号：US20110046363A1

  公开（公告）日：2011-02-24

  A process for the preparation of cladribine of API grade is provided by direct coupling of O-protected 2-deoxy-ribofuranose with silylated 2-chloroadenine followed by deprotection of the resultant protected nucleoside in a separate step and then a purification step. Following the coupling, the desired N-9-glycosylated β-anomer of the nucleoside is directly isolated as a solid from the coupling reaction mixture by filtration in relatively high purity and yield, and it does not require purification.

  提供了一种制备API级别的克拉布林的方法，该方法通过保护O-2-脱氧核糖苷与硅化2-氯腺嘌呤直接偶联，然后在单独的步骤中去保护得到的保护核苷酸，最后进行纯化步骤。在偶联之后，所需的核苷酸的N-9-糖基化β-异构体可以直接从偶联反应混合物中通过过滤以相对较高的纯度和收率作为固体分离出来，而且不需要纯化。
• Process for the preparation of cladribine
  申请人：Scinopharm (Kunshan) Biochemical Technology Co., Ltd.

  公开号：EP2891660A1

  公开（公告）日：2015-07-08

  A method of making cladribine with an increased purity is provided by a) dissolving crude cladribine in a protic solvent in the presence of a base to form a solution comprising dissolved crude cladribine; b) maintaining the solution at an elevated temperature so that the solution is homogeneous until the amount of protected or partially protected nucleoside impurities in the solution is reduced to a pre-determined upper limit; c) cooling the solution of step b) so that crystals of cladribine are formed and isolated.

  提供了一种制备纯度增加的克拉德利宾的方法，包括a)在碱的存在下将粗克拉德利宾溶解于质子溶剂中，形成包含已溶解的粗克拉德利宾的溶液；b)将溶液保持在升高的温度下，使溶液均匀，直到溶液中的受保护或部分受保护的核苷杂质量减少到预定的上限；c)冷却步骤b）的溶液，使克拉德利宾晶体形成并被分离。
• METHOD FOR THE PREPARATION OF 2-HALO-2'-DEOXYADENOSINE COMPOUNDS FROM 2'-DEOXYGUANOSINE
  申请人：Robins Morris J.

  公开号：US20090270604A1

  公开（公告）日：2009-10-29

  The present invention is a method for preparing 2-halo-6-aminopurines, and more specifically for preparing the clinical agent cladribine (2-chloro-2′-deoxyadenosine, CldAdo, 4), a drug of choice against hairy-cell leukemia and other neoplasms, from 2-amino-6-oxopurines, which are readily obtained from the naturally occurring compound 2′-deoxyguanosine. According to the methods of the present invention, the 6-oxo group of a protected 2′-deoxyguanosine (1) is converted to a 6-(substituted oxy) leaving group, or alternatively to a 6-chloro leaving group, the 2-amino group is replaced with a 2-chloro group, the 6-(substituted oxy) leaving group, or alternatively the 6-chloro leaving group, is replaced with a 6-amino group or, alternatively, a 2,6-dichloro substituted compound is selectively replaced with a 6-amino group, and the protecting groups are removed.

  本发明涉及制备2-卤代-6-氨基嘌呤，更具体地说，从2-氨基-6-氧代嘌呤制备临床药物克拉德霉素（2-氯-2'-脱氧腺苷，CldAdo，4），这是针对毛细胞白血病和其他肿瘤的首选药物。2-氨基-6-氧代嘌呤可以从天然存在的2'-脱氧鸟苷中轻松获得。根据本发明的方法，保护的2'-脱氧鸟苷（1）的6-氧代基被转化为6-（取代氧）离去基，或者被转化为6-氯离去基，2-氨基被2-氯代基取代，6-（取代氧）离去基或6-氯离去基被6-氨基取代，或者选择性地用6-氨基取代2,6-二氯取代化合物，并去除保护基。
• Method for the preparation of 2-halo-2'-deoxyadenosine compounds for 2'-deoxyguanosine
  申请人：Robins J. Morris

  公开号：US20070032645A1

  公开（公告）日：2007-02-08

  The present invention is a method for preparing 2-halo-6-aminopurines, and more specifically for preparing the clinical agent cladribine (2-chloro-2′-deoxyadenosine, CldAdo, 4), a drug of choice against hairy-cell leukemia and other neoplasms, from 2-amino-6-oxopurines, which are readily obtained from the naturally occurring compound 2′-deoxyguanosine. According to the methods of the present invention, the 6-oxo group of a protected 2′-deoxyguanosine (1) is converted to a 6-(substituted oxy) leaving group, or alternatively to a 6-chloro leaving group, the 2-amino group is replaced with a 2-chloro group, the 6-(substituted oxy) leaving group, or alternatively the 6-chloro leaving group, is replaced with a 6-amino group or, alternatively, a 2,6-dichloro substituted compound is selectively replaced with a 6-amino group, and the protecting groups are removed.

  本发明涉及一种制备2-卤代-6-氨基嘌呤的方法，更具体地说，是从2-氨基-6-氧代嘌呤制备临床药物克拉德霉素（2-氯-2'-脱氧腺苷，CldAdo，4），这是一种用于治疗毛细胞白血病和其他肿瘤的首选药物。2-氨基-6-氧代嘌呤是从天然存在的2'-脱氧鸟苷中容易得到的。根据本发明的方法，保护的2'-脱氧鸟苷（1）的6-氧代基被转化为6-(取代氧)离去基，或者替代为6-氯离去基，2-氨基被替换为2-氯基，6-(取代氧)离去基或者6-氯离去基被替换为6-氨基或者2,6-二氯取代化合物被选择性地替换为6-氨基，并去除保护基。